Free Trial
→ Your book attached (From Profits Run) (Ad)tc pixel Free RPRX Stock Alerts

Royalty Pharma (RPRX) Stock Forecast & Price Target

Royalty Pharma logo
$54.66 +0.39 (+0.72%)
As of 09:30 AM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare

Royalty Pharma - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Buy
Based on 7 Analyst Ratings
Sell
0
Hold
0
Buy
7

Based on 7 Wall Street analysts who have issued ratings for Royalty Pharma in the last 12 months, the stock has a consensus rating of "Buy." Out of the 7 analysts, 7 have given a buy rating for RPRX.

Consensus Price Target

$53.71
-1.73% Downside
According to the 7 analysts' twelve-month price targets for Royalty Pharma, the average price target is $53.71. The highest price target for RPRX is $66.00, while the lowest price target for RPRX is $42.00. The average price target represents a forecasted downside of -1.73% from the current price of $54.66.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for RPRX and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Royalty Pharma and its competitors.

Sign Up
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

RPRX Analyst Ratings Over Time

TypeCurrent Forecast
6/16/25 to 6/16/26		1 Month Ago
5/17/25 to 5/17/26		3 Months Ago
3/18/25 to 3/18/26		1 Year Ago
6/16/24 to 6/16/25
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
1 Strong Buy rating(s)
Buy
7 Buy rating(s)
7 Buy rating(s)
6 Buy rating(s)
3 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$53.71$53.71$48.67$47.33
Forecasted Upside-1.73% Downside1.64% Upside6.28% Upside34.85% Upside
Consensus RatingBuyBuyBuyBuy

RPRX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

RPRX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Royalty Pharma Stock vs. The Competition

TypeRoyalty PharmaMedical CompaniesBroader Market
Consensus Rating Score
3.00
2.29
2.52
Consensus RatingBuyHoldModerate Buy
Predicted Upside-1.02% Downside661.76% Upside13.99% Upside
News Sentiment Rating
Positive News

See Recent RPRX News
Positive News
Positive News
Export
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside		Details
5/15/2026
Weiss Ratings logo
Weiss Ratings
5 of 5 stars
 DowngradeBuy (B) ➝ Buy (B-)
5/7/2026
Citigroup Inc. logo
Citigroup
4 of 5 stars
Geoff Meacham
Geoff Meacham
5 of 5 stars
Boost TargetBuy$50.00 ➝ $66.00+31.47%
5/7/2026
JPMorgan Chase & Co. logo
JPMorgan Chase & Co.
3 of 5 stars
Chris Schott
5 of 5 stars
Boost TargetOverweight$50.00 ➝ $58.00+15.75%
4/21/2026
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Ashwani Verma
Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating
Boost TargetBuy$51.00 ➝ $57.00+15.62%
4/10/2026
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Terence Flynn
Terence Flynn
Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating
Boost TargetOverweight$61.00 ➝ $63.00+31.62%
2/27/2026
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Steve Scala
Steve Scala
Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating
Reiterated RatingBuy
2/12/2026
The Goldman Sachs Group, Inc. logo
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Asad Haider
Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating
Reiterated RatingBuy
12/11/2025
Leerink Partners logo
Leerink Partners
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Set Target$45.00+17.68%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 09:32 AM ET.


Should I Buy Royalty Pharma Stock? RPRX Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Friday, June 12, 2026. Please send any questions or comments about these Royalty Pharma pros and cons to contact@marketbeat.com.

Royalty Pharma
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Royalty Pharma plc:

  • The current stock price is around $56, reflecting a strong performance in the market and investor confidence.
  • Royalty Pharma plc has a solid dividend yield of approximately 1.7%, providing a steady income stream for investors.
  • The company has received multiple upgrades from analysts, indicating positive sentiment and potential for future growth.
  • With a market capitalization of over $32 billion, Royalty Pharma plc is well-positioned in the biopharmaceutical sector, suggesting stability and resilience.
  • The firm reported a net margin of nearly 34%, showcasing its efficiency in converting revenue into profit.

Royalty Pharma
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Royalty Pharma plc for these reasons:

  • The company has a relatively high P/E ratio of about 37.84, which may indicate that the stock is overvalued compared to its earnings.
  • Royalty Pharma plc's revenue for the latest quarter fell short of analyst estimates, raising concerns about its growth trajectory.
  • The payout ratio is currently at 63.95%, which may limit the company's ability to reinvest in growth opportunities.
  • Despite a strong market position, the stock has experienced volatility, which could pose risks for conservative investors.
  • The company operates in a highly competitive industry, which may impact its long-term profitability and market share.

RPRX Forecast - Frequently Asked Questions

According to the research reports of 7 Wall Street equities research analysts, the average twelve-month stock price forecast for Royalty Pharma is $53.71, with a high forecast of $66.00 and a low forecast of $42.00.

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Royalty Pharma in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" RPRX shares.

According to analysts, Royalty Pharma's stock has a predicted downside of -1.73% based on their 12-month stock forecasts.

Over the previous 90 days, Royalty Pharma's stock had 1 upgrade and 1 downgrade by analysts.

Royalty Pharma has been rated by research analysts at Citigroup, JPMorgan Chase & Co., Morgan Stanley, UBS Group, and Weiss Ratings in the past 90 days.

Analysts like Royalty Pharma more than other "medical" companies. The consensus rating for Royalty Pharma is Buy while the average consensus rating for "medical" companies is Hold. Learn more on how RPRX compares to other companies.

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Royalty Pharma Recommendations


This page (NASDAQ:RPRX) was last updated on 6/16/2026 by MarketBeat.com Staff.
From Our Partners
VWAV: The Defense Tech Story Going Unnoticed!
As global defense spending accelerates, VisionWave Holdings (NASDAQ: VWAV) is developing a full-stack intellig...
Equiscreen | Sponsoredtc pixel
SpaceX IPO hides a much bigger story
The SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...
Weiss Ratings | Sponsoredtc pixel
How to play the Biggest IPO in stock market history!
SpaceX is eyeing a near-$2 trillion IPO valuation, and retail investors are already lining up - but early insi...
InvestPub | Sponsoredtc pixel
Rickards Predicts: Trump to buy tiny $2 stock?
Jim Rickards believes the Trump administration is about to take a direct stake in a $2 stock sitting on the la...
Paradigm Press | Sponsoredtc pixel
Read now. Do not delete. You’ve been warned.
Three Nobel Prize Winners expose this once-in-a-generation wealth shift: “Don’t Say I Didn’t Warn You” P...
Porter & Company | Sponsoredtc pixel
Do NOT Buy SpaceX – Do This Instead
SpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...
Stansberry Research | Sponsoredtc pixel
After “33X” call, Jon Najarian reveals NEW Tesla prediction…
Jon Najarian called Tesla a buy in 2014 before the stock climbed as high as 3,392%. He also called Palantir on...
Banyan Hill Publishing | Sponsoredtc pixel
The number nobody's bragging about
SPCX - the largest IPO in history - was predicted to open at $175. It opened at $150. Insiders bought in at a ...
Behind the Markets | Sponsoredtc pixel